Together, these findings not only extend our understanding of the molecular mechanisms driving cardiac sarcoidosis but also highlight potential targets, specifically the CSF1R and IL4R/Jak3/STAT6 pathways, for therapeutic intervention aimed at modulating macrophage responses and mitigating tissue damage. This evidence concerns the gene STAT6 and cardiac sarcoidosis.